Pharming (PHAR) Non Operating Interest Expenses (2020 - 2021)

Pharming (PHAR) has 4 years of Non Operating Interest Expenses data on file, last reported at -$633000.0 in Q3 2023.

• Quarterly Non Operating Interest Expenses fell 152.84% year-over-year to -$633000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $3.1 million (down 17.77% YoY) and the FY2021 annual result came in at $8511.1, up 126.19% from the prior year.
• Non Operating Interest Expenses retreated to -$633000.0 in Q3 2023, from $1.2 million in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $12.3 million in Q3 2020 to a low of -$633000.0 in Q3 2023.
• A 4-year average of $2.6 million and a median of $616378.2 in 2022 frame the typical range for Non Operating Interest Expenses.
• Annual changes were most pronounced in 2022 — Non Operating Interest Expenses sank 52.44% — and 2023, when it tumbled 152.84%.
• Tracing PHAR's Non Operating Interest Expenses over 4 years: stood at $34756.4 in 2020, then sank by 82.8% to $5977.2 in 2021, then jumped by 19942.67% to $1.2 million in 2022, then plunged by 152.84% to -$633000.0 in 2023.
• The last three Non Operating Interest Expenses figures came in at -$633000.0 (Q3 2023), $1.2 million (Q3 2022), and $5977.2 (Q4 2021), per Business Quant data.